Compare Abbott Laboratories (ABT) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Johnson Controls International PLC — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Johnson Controls International PLC trades at $139.72 (market cap $85.79B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | JCI | |
|---|---|---|
Market Cap | $166.94B | $85.79B |
Sector | Health | Industrials |
52-Week High | $136.62 | $148.21 |
52-Week Low | $82.57 | $103.24 |
Enterprise Value | $193.69B | $94.62B |
Dividend Yield | 2.63% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Johnson Controls International (JCI) trades at $140.62, down 0.1% on the day, with strong analyst support showing 62% buy ratings and a consensus price target of $153.67. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.19 surpassing the $1.12 estimate. The company maintains solid profitability with a 14.45% net income margin and recently announced a $0.40 dividend payable in July 2026. Technical indicators show a bullish trend with support at $139 and resistance at $145.
JCI presents a favorable investment case with earnings momentum, strong analyst conviction, and exposure to growing markets like data center cooling. Key risks include elevated valuation multiples (P/E of 43.65) and increasing debt-to-asset ratios. The stock's current price offers approximately 9% upside to consensus targets, though investors should monitor execution on revenue growth projections and competitive pressures in the building solutions sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
